Figure 3
Figure 3. CCR6 is necessary to the intracellular HIV-inhibitory activity of hBD2. JKT-FT7 (CCR6low/no) and JKT-FT7 CCR6 GFP (CCR6+) cells were infected with HIV-luciferase pseudotyped with AMLV envelope. After infection, cells were incubated 3 days in complete RPMI, with or without hBD2 (20 μg/mL). Subsequently, cells were washed and lysed, and luciferase activity was measured. The percentage of inhibition was calculated in reference to luciferase activity as measured in untreated control infections. Shown here are the average percentage of inhibition values (± SEMs) of 3 independent experiments. *P < .05 (2-tailed t test) between homologous treatment groups for CCR6low/no and CCR6+ cells.

CCR6 is necessary to the intracellular HIV-inhibitory activity of hBD2. JKT-FT7 (CCR6low/no) and JKT-FT7 CCR6 GFP (CCR6+) cells were infected with HIV-luciferase pseudotyped with AMLV envelope. After infection, cells were incubated 3 days in complete RPMI, with or without hBD2 (20 μg/mL). Subsequently, cells were washed and lysed, and luciferase activity was measured. The percentage of inhibition was calculated in reference to luciferase activity as measured in untreated control infections. Shown here are the average percentage of inhibition values (± SEMs) of 3 independent experiments. *P < .05 (2-tailed t test) between homologous treatment groups for CCR6low/no and CCR6+ cells.

Close Modal

or Create an Account

Close Modal
Close Modal